Question 1

What does HER2 status mean in gastric cancer?

Accepted Answer

HER2 is a protein found on the surface of all cells, but in some gastric and gastroesophageal cancers the cancer cells make far too much of it. This is referred to as HER2-positive disease and tends to drive faster growth. HER2 status is one of the most important biological markers in gastric cancer research, and a family of treatments, including targeted therapies and antibody-drug conjugates, has been developed specifically to act on tumours that carry it.

Question 2

What is claudin 18.2 in gastric cancer?

Accepted Answer

Claudin 18.2 is a protein that helps form tight seals between healthy stomach cells, but it's also expressed on the surface of many gastric and gastroesophageal cancers. Because claudin 18.2 is largely confined to stomach tissue and tumours, it's an attractive target. Multiple classes of treatment, including antibody-based therapies, antibody-drug conjugates, and cell therapies, are being developed to act on cancers that carry it. It's one of the most active areas of research in gastric cancer.

Question 3

Why is the gastroesophageal junction studied alongside both gastric and oesophageal cancers?

Accepted Answer

The gastroesophageal junction is the area where the lower oesophagus joins the stomach. Cancers that arise here share biological features with both oesophageal adenocarcinoma and gastric cancer, and they're often grouped with whichever disease they most resemble. As a result, junction cancers sit at the overlap of gastric and oesophageal cancer research, and biological markers like HER2 and claudin 18.2 are studied across both.

Gastric (Stomach) Cancer clinical trials in Australia

Three steps. About 30 seconds.

Describe

Match

Discuss

Gastric (Stomach) Cancer clinical trials: common questions

Search other cancer types